Losartan Potassium Tablet, Film Coated
Product Images NDC 62332-028

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 62332-028). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Losartan Fig1)

Figure 1 (Losartan Fig1)
This appears to be a chart or graph presenting data from a clinical study involving Atenolol and Losartan Potassium Tablets used to treat patients with an unspecified condition. The chart shows the study month on the X-axis and the percentage of patients with a primary endpoint on the Y-axis. An adjusted risk reduction of 13% is mentioned with a p-value of .021. Further information on the study is not available.*
FDA Label Image

Figure 2 (Losartan Fig2)

Figure 2 (Losartan Fig2)
This is a statistic that compares the efficacy of two different medications, atenolol and losartan potassium tablets, in reducing the risk of fatal/non-fatal stroke in patients. The adjusted risk reduction with losartan potassium tablets is 25%, which is statistically significant with a p-value of 0.001. The data is presented over a course of 66 months of the study.*
FDA Label Image

Figure 3 (Losartan Fig3)

Figure 3 (Losartan Fig3)
This text presents a table containing data on primary endpoint events for different demographic subgroups in a study comparing the effectiveness and safety of Losartan potassium tablets and Atenolol. The primary composite endpoint was a fatal or non-fatal stroke. The table includes subgroups based on age, gender, race, history of cardiovascular disease, Hypertension (IsH), and diabetes. The rates and hazard ratios of primary endpoint events are provided. The table concludes with information on the proportionality of symbols used in the table and the adjustment of the baseline Framingham risk score and level of electrocardiographic ventricular hypertrophy.*
FDA Label Image

Figure 4 (Losartan Fig4)

Figure 4 (Losartan Fig4)
The text describes a graph that displays the percentage of patients who experienced an event and the risk reduction percentage for a certain medication (Losartan Potassium Tablets) compared to a placebo. The graph displays a timeline of 48 units and shows that the medication had a 16.1% risk reduction compared to the placebo. The statistical significance is indicated by a p-value of 0.022.*
FDA Label Image

Losartan mg100

Losartan mg100
This is information about Losartan Potassium tablets, USP, manufactured by Alembic Pharmaceutical in India and sold in the United States. The usual adult dosage is not specified and is contained in accompanying material. The tablets contain 100mg of Losartan. They should be stored between 15°C to 30°C and kept in a closed container. The pharmacist is instructed to dispense with the patient information leaflet. The tablets come in a pack of 30 and are available by prescription only.*
FDA Label Image

Losartan mg25

Losartan mg25
This is information about Losartan Potassium tablets, USP, manufactured by Alembic Pharmaceutical Limited in India. The tablets contain 25mg of Losartan Potassium and the usual adult dosage information can be found in an accompanying leaflet. They should be stored at room temperature and protected from light. The product should be kept tightly closed. The packaging includes an NDC code and a GTIN.*
FDA Label Image

Losartan mg50

Losartan mg50
This is a description of a medication named Losartan Potassium. It is in tablet form and its National Drug Code (NDC) is 62332-028-30. The tablets should be stored at a controlled room temperature of 25°C (77°F) and the container should be kept tightly closed. There is a coding area that should not be printed, and the medication is produced by a company called Alembic Pharmaceuticals located in Bedminster, NJ, USA. The has also included some random characters and numbers that are not readable.*
FDA Label Image

Structure (Losartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.